¼¼°èÀÇ ºñÈ£ÁöŲ¸²ÇÁÁ¾(NHL) Ä¡·á ½ÃÀå(2024-2028³â)
Global Non-hodgkin Lymphoma (NHL) Therapeutics Market 2024-2028
»óǰÄÚµå : 1544396
¸®¼­Ä¡»ç : TechNavio
¹ßÇàÀÏ : 2024³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 190 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 2,500 £Ü 3,532,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 4,000 £Ü 5,652,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

ºñÈ£ÁöŲ¸²ÇÁÁ¾(NHL) Ä¡·á ½ÃÀåÀº 2023-2028³â 69¾ï 5,650¸¸ ´Þ·¯·Î ¿¹ÃøµÇ¸ç, ¿¹Ãø ±â°£ µ¿¾È 9.45%ÀÇ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ º¸°í¼­´Â ºñÈ£ÁöŲ¸²ÇÁÁ¾(NHL) Ä¡·á ½ÃÀå¿¡ ´ëÇÑ Àü¹ÝÀûÀÎ ºÐ¼®, ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, µ¿Çâ, ¼ºÀå ÃËÁø¿äÀÎ, °úÁ¦, ¾à 25°³ º¥´õ¿¡ ´ëÇÑ º¥´õ ºÐ¼® µîÀÇ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.

ÇöÀç ½ÃÀå ½Ã³ª¸®¿À, Ãֽе¿Çâ ¹× ÃËÁø¿äÀÎ, Àüü ½ÃÀå ȯ°æ¿¡ ´ëÇÑ ÃֽŠºÐ¼®À» Á¦°øÇÕ´Ï´Ù. ÃÖ±Ù ½ÂÀÎ, °­·ÂÇÑ ÆÄÀÌÇÁ¶óÀÎ, ³ëÀÎ Àα¸ Áõ°¡, Ưȿ¾à ÁöÁ¤ µîÀÌ ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù.

½ÃÀå ¹üÀ§
±âÁØ ¿¬µµ 2024³â
Á¾·á ¿¬µµ 2028³â
¿¹Ãø ±â°£ 2024-2028³â
¼ºÀå ¸ð¸àÅÒ °¡¼Ó
Àü³â ´ëºñ[2024³â] 8.42%
CAGR 9.45%
ÁõºÐ ±Ý¾× 69¾ï 5,650¸¸ ´Þ·¯

ÀÌ º¸°í¼­´Â ÇâÈÄ ¸î ³â µ¿¾È ºñÈ£ÁöŲ¸²ÇÁÁ¾(NHL) Ä¡·á ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎ Áß Çϳª·Î ¿¬±¸ º¸Á¶±Ý°ú ÀÚ±Ý Áö¿øÀ» ²Å¾Ò½À´Ï´Ù. ¶ÇÇÑ, ¾Ï¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í ȯÀÚ Áö¿ø ÇÁ·Î±×·¥ ¹× »óȯ±ÝÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ½ÃÀå ¼ö¿ä°¡ Å©°Ô Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå »óȲ

Á¦3Àå ½ÃÀå ±Ô¸ð Æò°¡

Á¦4Àå ½ÃÀå ±Ô¸ð ½ÇÀû

Á¦5Àå Five Forces ºÐ¼®

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­ : À¯Åë ä³Îº°

Á¦7Àå ½ÃÀå ¼¼ºÐÈ­ : ¿ä¹ýº°

Á¦8Àå °í°´ »óȲ

Á¦9Àå Áö¿ªº° »óȲ

Á¦10Àå ÃËÁø¿äÀÎ, °úÁ¦, ±âȸ, ¾ïÁ¦¿äÀÎ

Á¦11Àå °æÀï »óȲ

Á¦12Àå °æÀï ºÐ¼®

Á¦13Àå ºÎ·Ï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The non-hodgkin lymphoma (NHL) therapeutics market is forecasted to grow by USD 6956.5 mn during 2023-2028, accelerating at a CAGR of 9.45% during the forecast period. The report on the non-hodgkin lymphoma (NHL) therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by recent approvals and strong pipeline, growing geriatric population, and special drug designations.

Technavio's non-hodgkin lymphoma (NHL) therapeutics market is segmented as below:

Market Scope
Base Year2024
End Year2028
Series Year2024-2028
Growth MomentumAccelerate
YOY 20248.42%
CAGR9.45%
Incremental Value$6956.5 mn

By Distribution Channel

By Therapy

By Geographical Landscape

This study identifies the research grants and funding as one of the prime reasons driving the non-hodgkin lymphoma (NHL) therapeutics market growth during the next few years. Also, growing awareness about cancer and increase in patient assistance programs and reimbursements will lead to sizable demand in the market.

The report on the non-hodgkin lymphoma (NHL) therapeutics market covers the following areas:

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading non-hodgkin lymphoma (NHL) therapeutics market vendors that include AstraZeneca PLC, Baxter International Inc., Bayer AG, BeiGene Ltd., Biogen Inc., Bristol Myers Squibb Co., Eisai Co. Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline PLC, Johnson and Johnson Services Inc., Merck KGaA, Novartis AG, Pfizer Inc., Takeda Pharmaceutical Co. Ltd., and Teva Pharmaceutical Industries Ltd.. Also, the non-hodgkin lymphoma (NHL) therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

1 Executive Summary

2 Market Landscape

3 Market Sizing

4 Historic Market Size

5 Five Forces Analysis

6 Market Segmentation by Distribution Channel

7 Market Segmentation by Therapy

8 Customer Landscape

9 Geographic Landscape

10 Drivers, Challenges, and Opportunity/Restraints

11 Competitive Landscape

12 Competitive Analysis

13 Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â